| 黄达荣.桂枝茯苓丸加味牛膝、大黄治疗血瘀型AECOPD临床疗效观察[J].浙江中西医结合杂志,2025,35(12): |
| 桂枝茯苓丸加味牛膝、大黄治疗血瘀型AECOPD临床疗效观察 |
|
| 投稿时间：2025-03-10 修订日期：2025-06-23 |
| DOI： |
| 中文关键词: 桂枝茯苓丸 牛膝 大黄 血瘀型 慢性阻塞性肺疾病 |
| 英文关键词:Guizhi Fuling Pill Achyranthes bidentata Rheum palmatum Blood stasis type? Chronic obstructive pulmonary disease |
| 基金项目:杭州市农业与社会发展科研引导项目 (20201231Y146 ) |
|
| 摘要点击次数: 100 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【摘要】目的 观察桂枝茯苓丸加味牛膝、大黄治疗血瘀型AECOPD的临床疗效。方法 选取2021年1月至2022年12月AECOPD病人100例，分为对照组和观察组，每组各50例。对照组用西药常规治疗，观察组在西药常规治疗的基础上联合桂枝茯苓丸加味牛膝、大黄汤剂口服，疗程10d。采用实验室血液指标（D-Dimer、IL-6、Pa02、PaCO2）、 肺功能指标（FEV1、FVC）。结果 两组比较，观察组总疗效明显优于对照组(P<0.01)，观察组实验室血液指标改善优于对照组（P＜0.05），观察组肺功能（FEV1、FVC）指标改善优于对照组(P<0.05)。结论 桂枝茯苓丸加味牛膝、大黄汤剂治疗血瘀型慢性阻塞性肺疾病急性加重期疗效显著，可以有效降低D-Dimer、IL-6指标，改善Pa02、PaCO2及肺功能（FEV1、FVC）指标，提高患者生活质量。 |
| 英文摘要: |
| [Abstract] Objective: To observe the clinical efficacy of Guizhi Fuling Pill with added Achyranthes bidentata and Rheum palmatum in treating AECOPD of blood stasis type。Methods: A total of 100 patients with AECOPD from January 2021 to December 2022 were selected and divided into a control group and an observation group, with 50 cases in each group. The control group received conventional Western medicine treatment, while the observation group was treated with a combination of conventional Western medicine and Guizhi Fuling Pill with added Achyranthes bidentata and Rheum palmatum decoction orally. The treatment course was 10 days. Laboratory blood indicators (D-Dimer, IL-6, PaO?, PaCO?) and pulmonary function indicators (FEV?, FVC) were used for evaluation。Results: Compared with the control group, the observation group showed significantly better overall therapeutic effect (P < 0.01). The improvement in laboratory blood indicators was superior in the observation group (P < 0.05), and the pulmonary function indicators (FEV?, FVC) also showed better improvement in the observation group (P < 0.05)。Conclusion: Guizhi Fuling Pill with added Achyranthes bidentata and Rheum palmatum decoction is highly effective in treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of blood stasis type. It can effectively reduce the levels of D-Dimer and IL-6, improve PaO?, PaCO?, and pulmonary function indicators (FEV?, FVC), and enhance the quality of life of patients。 |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
